Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP

While chimeric antigen receptor (CAR) T–cell therapy has revolutionized the treatment landscape for multiple myeloma, the high demand for these efficacious therapies has made patient selection a challenge. At the recent International Myeloma Society Annual Meeting, Beth Faiman, a Nurse Practitioner at the Cleveland Clinic, presented a poster about a clinical factor scoring system that she and her colleagues have developed to aid in these decisions. In this follow-up interview with Oncology Data Advisor, Dr. Faiman explains how this innovative system works and the next steps to validate it and implement it into practice in the future.  

Continue reading

Addressing Clinical Trial Accrual of Minority Patients With Donna Catamero, NP

At the recent International Myeloma Society (IMS) Annual Meeting, Donna Catamero, NP, the Associate Director of Myeloma Translational Research at Mount Sinai Hospital, presented her abstract regarding increasing clinical trial accrual of minority patients. In this interview, Ms. Catamero discusses her presentation, the disproportionate burden that minority patients experience, and why she believes the health care team should take action to create an equal space for everyone in the clinic.  

Continue reading

No One Left Alone: Taking the First Steps to Address Cancer Disparities With Kashyap Patel, MD

At the recent International Myeloma Society (IMS) Annual Meeting, Dr. Kashyap Patel, CEO of Carolina Blood and Cancer Care Associates and President of the Community Oncology Alliance, spoke about practical solutions for addressing disparities in multiple myeloma in the United States. In this follow-up interview with Oncology Data Advisor, Dr. Patel digs deep into the multifaceted factors that contribute to cancer disparities and shares his pioneering work that aims to ensure that every patient with cancer receives equitable access to care.  

Continue reading

Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP

While chimeric antigen receptor (CAR) T–cell therapy has revolutionized the treatment landscape for multiple myeloma, the high demand for these efficacious therapies has made patient selection a challenge. At the recent International Myeloma Society Annual Meeting, Beth Faiman, a Nurse Practitioner at the Cleveland Clinic, presented a poster about a clinical factor scoring system that she and her colleagues have developed to aid in these decisions. In this follow-up interview with Oncology Data Advisor, Dr. Faiman explains how this innovative system works and the next steps to validate it and implement it into practice in the future.  

Continue reading

No One Left Alone: Taking the First Steps to Address Cancer Disparities With Kashyap Patel, MD

At the recent International Myeloma Society (IMS) Annual Meeting, Dr. Kashyap Patel, CEO of Carolina Blood and Cancer Care Associates and President of the Community Oncology Alliance, spoke about practical solutions for addressing disparities in multiple myeloma in the United States. In this follow-up interview with Oncology Data Advisor, Dr. Patel digs deep into the multifaceted factors that contribute to cancer disparities and shares his pioneering work that aims to ensure that every patient with cancer receives equitable access to care.  

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.